List view / Grid view
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
A Phase I/IIa study has shown that arfolitixorin along with either irinotecan or oxaliplatin could shrink the size of tumours in colorectal cancer patients...
A new study reveals the efficacy and safety of using intravenous bevacizumab to treat patients with severe hereditary haemorrhagic telangiectasia (HHT). Successful results suggest it should be used as a first-line therapy.
The European Commission has granted marketing authorisation for Mvasi for the treatment of certain types of cancer...